Clinical Trials
2 trialsNCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT02250872 2016-04-20
Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury
Seoul National University Bundang Hospital
Phase 2/3 Unknown